Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Young and Elite Researchers Club, Parand Branch, Islamic Azad University, Parand, Iran.
Neurol Sci. 2021 Sep;42(9):3791-3799. doi: 10.1007/s10072-020-04979-1. Epub 2021 Jan 16.
Multiple sclerosis (MS) is a chronic, demyelinating disease in which the neuron myelin sheath is disrupted and leading to signal transductions disabilities. The evidence demonstrated that gene expression patterns and their related regulating factors are the most critical agents in MS demyelinating process. A miRNA is a small non-coding RNA which functions in post-transcriptional regulation of gene expression. Identification of specific miRNA dysregulation patterns in MS blood samples compared to healthy control can be used as a diagnostic and prognostic agent. Through the literature review and bioinformatics analysis, it was found that the hsa-miR-106a-5p can be considered a significant MS pathogenic factor, which seems has an abnormal expression pattern in patients' blood. Experimental validation using real-time PCR assay was carried to verifying the miR-106a-5p expression in MS and healthy control blood samples. The obtained results proved the miR-106a dysregulation in MS patients. The expression levels of miR-106a-5p were significantly downregulated (log 2 fold change = - 1.15) in patient blood samples compared to controls (p = 0.055). Our study suggested that miR-106a-5p may have a biomarker potential to the diagnosis of MS patients based on its dysregulation patterns.
多发性硬化症（MS）是一种慢性脱髓鞘疾病，其中神经元髓鞘被破坏，导致信号转导障碍。有证据表明，基因表达模式及其相关调节因子是 MS 脱髓鞘过程中最关键的因素。miRNA 是一种小的非编码 RNA，在基因表达的转录后调控中发挥作用。与健康对照组相比，在 MS 血液样本中鉴定出特定的 miRNA 失调模式可作为诊断和预后标志物。通过文献回顾和生物信息学分析，发现 hsa-miR-106a-5p 可被视为重要的 MS 致病因素，其在患者血液中似乎存在异常表达模式。通过实时 PCR 检测进行实验验证，以验证 MS 和健康对照组血液样本中的 miR-106a-5p 表达。获得的结果证明了 MS 患者中 miR-106a 的失调。与对照组相比，患者血液样本中 miR-106a-5p 的表达水平显著下调（log2 倍数变化=−1.15）（p=0.055）。我们的研究表明，基于其失调模式，miR-106a-5p 可能具有作为 MS 患者诊断的生物标志物潜力。
